

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3225545

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	UCB S.A.	11/14/2005
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	ACTELION PHARMACEUTICALS LTD	
<b>Street Address:</b>	GEWERBESTRASSE 16	
<b>City:</b>	ALLSCHWIL	
<b>State/Country:</b>	SWITZERLAND	
<b>Postal Code:</b>	CH-4123	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	14246879
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(973)912-5236	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	973-912-5232	
<b>Email:</b>	hoxiepatentmail@hoxpat.com	
<b>Correspondent Name:</b>	HOXIE & ASSOCIATES LLC	
<b>Address Line 1:</b>	75 MAIN STREET, SUITE 203	
<b>Address Line 4:</b>	MILLBURN, NEW JERSEY 07041	
<b>ATTORNEY DOCKET NUMBER:</b>	AC-23-USC	
<b>NAME OF SUBMITTER:</b>	BRITTANY LA	
<b>SIGNATURE:</b>	/Brittany La/	
<b>DATE SIGNED:</b>	02/13/2015	
<b>Total Attachments: 9</b>		
source=AC-23-USC - UCB-Actelion Assignment#page1.tif		
source=AC-23-USC - UCB-Actelion Assignment#page2.tif		
source=AC-23-USC - UCB-Actelion Assignment#page3.tif		
source=AC-23-USC - UCB-Actelion Assignment#page4.tif		
source=AC-23-USC - UCB-Actelion Assignment#page5.tif		
source=AC-23-USC - UCB-Actelion Assignment#page6.tif		

source=AC-23-USC - UCB-Actelion Assignment#page7.tif

source=AC-23-USC - UCB-Actelion Assignment#page8.tif

source=AC-23-USC - UCB-Actelion Assignment#page9.tif

**DATED: 14<sup>th</sup> NOVEMBER 2005**

**UCB S.A.  
acting through its UK branch office  
UCB Celltech**

**AND**

**ACTELION PHARMACEUTICALS LTD**

---

**PATENT ASSIGNMENT**

---

This assignment is made the 14<sup>th</sup> day of November 2005

**Between:**

UCB S.A, a Belgium company, having its registered office at Allée de la Recherche 60, B-1070 Brussels, Belgium, acting through its UK branch office UCB Celltech ("UCB"), the legal successor of Oxford Glycosciences (UK) Limited, whose registered office was situated at 208 Bath Road, Slough, Berkshire SL1 3WE, England ("OGS")

on the one hand,

and

ACTELION PHARMACEUTICALS LTD a Swiss company, having its principal place of business at Gewerbstrasse 16, Allschwil 4123, Switzerland ("Actelion"),

on the other hand.

**BACKGROUND**

- (A) UCB is the owner of the patents, and has applied for the patent applications, each listed in the Schedule to this assignment ("Patents").
- (B) As part of an assignment, licence and supply agreement between UCB and Actelion dated the same date as this assignment (the "Agreement"), UCB agreed to assign the Patents to Actelion.
- (C) The Parties now wish to give full effect to the Agreement by entering into this assignment.


**IT IS AGREED:**

- 1. In consideration of payment by Actelion to UCB of the sum of £1 (one pound sterling) (receipt of which is acknowledged by the UCB), UCB hereby sells, assigns and transfers to Actelion such right, title and interest as it holds in the Patents.
- 2. This assignment includes the right (where applicable) to file applications under the Paris Convention, corresponding to or based on any of the applications for Patents, and to claim priority from those applications.
- 3. Actelion acknowledges that UCB gives no representation, warranty, indemnity or guarantee in respect of any of the Patents, in this assignment, but this is without prejudice to the provisions of the Agreement.
- 4. This assignment is governed by the substantive law of England. The Parties agree that the English courts are to have jurisdiction to settle any disputes which may arise in connection with this assignment and that any proceedings arising in connection with this assignment may be brought to those courts.

5. This assignment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS whereof the Parties hereto have executed this assignment the day and year first above written

SIGNED for and on behalf of **UCB S.A** )  
(acting through its UK branch office UCB Celltech) )  
by )



Name: Robert J. Pralor  
Title: Senior Vice President,  
Corporate And General Counsel



Name: Melanie Lee  
Title: Executive Vice President  
R&D

SIGNED for and on behalf of )  
**Actellon Pharmaceuticals Ltd** by )



Name: Dr Jean-Paul Clozel  
Title: Chief Executive Officer



Name: Dr Marian Borovsky  
Title: General Counsel

**SCHEDULE: LIST OF OGS PATENTS**

## SCHEDULE: LIST OF OGS PATENTS

(Case Ref. P0025)

Territory	Application No.	Application date	Patent No.	Date of grant
Australia	41333/00	20 Apr. 2000	776 947	30 Sep. 2004
Brazil	PI0009868.0	20 Apr. 2000		
Canada	2 368 814	20 Apr. 2000		
European Patent <sup>1</sup>	00920922.2	20 Apr. 2000		
Israel	145907	20 Apr. 2000		
Japan	2000/611916	20 Apr. 2000		
Mexico	PA/a/2001/010706	20 Apr. 2000		
Norway	20015112	20 Apr. 2000		
South Africa	2001/8413	20 Apr. 2000	2001/8413	13 Jan. 2003
United States	10/007,306	19 Oct. 2001	6,683,076	27 Jan. 2004

<sup>1</sup> designating the following countries: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Portugal, Spain, Sweden and Switzerland/Liechtenstein.

(Case Ref. P0026)

<b>Territory</b>	<b>Application No.</b>	<b>Application date</b>	<b>Patent No.</b>	<b>Date of grant</b>
Australia	41332/00	20 Apr. 2000	775 842	19 Aug. 2004
Brazil	PI0009913.9	20 Apr. 2000		
Canada	2 368 812	20 Apr. 2000		
European Patent *	00920920.6	20 Apr. 2000	1 171 128	18 Jun. 2003
European Patent °	03005215.3	20 Apr. 2000		
Israel	140379	20 Apr. 2000		
Japan	2000/611915	20 Apr. 2000		
Mexico	PA/a/2001/010707	20 Apr. 2000		
Norway	20015111	20 Apr. 2000		
South Africa	2001/8417	20 Apr. 2000	2001/8417	13 Jan. 2003
United States	10/758,247	Jan. 15, 2004		

\* *in force in the following countries: Belgium, France, Germany, Great Britain, Italy, the Netherlands and Spain.*

° *designating the following countries: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Portugal, Spain, Sweden and Switzerland/Liechtenstein.*

(Case Ref. P0055 – co-owned with University of Oxford)

<b>Territory</b>	<b>Application No.</b>	<b>Application date</b>	<b>Patent No.</b>	<b>Date of grant</b>
Australia	2002219363	11 Jan. 2002		
Brazil	PI0206433-2	11 Jan. 2002		
Canada	2 433 675	11 Jan. 2002		
China	02806226.4	11 Jan. 2002		
European Patent <sup>1</sup>	02729458.6	11 Jan. 2002		
Hungary	P0303891	11 Jan. 2002		
Israel	156873	11 Jan. 2002		
Japan	2002-556170	11 Jan. 2002		
Mexico	PA/a/2003/006185	11 Jan. 2002		
Russian Federation	2003/24756	11 Jan. 2002		
Singapore	200303853-6	11 Jan. 2002		
South Africa	2003/5118	11 Jan. 2002		
South Korea	10-2003-7009309	11 Jan. 2002		
United States	11/196,153	03 Aug. 2005		

<sup>1</sup> designating the following countries: Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Portugal, Spain, Sweden, Switzerland/Liechtenstein and Turkey.



(Case Ref. P0116)

<b>Territory</b>	<b>Application No.</b>	<b>Application date</b>	<b>Patent No.</b>	<b>Date of grant</b>
United States	10/619,378	14 Jul. 2003		

(Case Ref. P0172a)

<b>Territory</b>	<b>Application No.</b>	<b>Application date</b>	<b>Patent No.</b>	<b>Date of grant</b>
Australia	2003248960	17 Jul. 2003		
Canada	2 492 410	17 Jul. 2003		
European Patent 1	03764031.5	17 Jul. 2003		
Japan	2004-520913	17 Jul. 2003		
United States	not yet known	17 Jul. 2003		

<sup>1</sup> designating the following countries: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Great Britain, Greece, Hungary, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland/Liechtenstein and Turkey.

(Case Ref. P0172b)

<b>Territory</b>	<b>Application No.</b>	<b>Application date</b>	<b>Patent No.</b>	<b>Date of grant</b>
Australia	2003246942	17 Jul. 2003		
Canada	2 492 404	17 Jul. 2003		
European Patent	03764025.7	17 Jul. 2003		
Japan	2004-520900	17 Jul. 2003		
United States	not yet known	17 Jul. 2003		

*\* designating the following countries: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Great Britain, Greece, Hungary, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland/Liechtenstein and Turkey.*

(Case Ref. P0194)

<b>Territory</b>	<b>Application No.</b>	<b>Application date</b>	<b>Patent No.</b>	<b>Date of grant</b>
PCT	PCT/GB04/002451	9. Jun. 2004		

(Case Ref. P0195)

<b>Territory</b>	<b>Application No.</b>	<b>Application date</b>	<b>Patent No.</b>	<b>Date of grant</b>
PCT	PCT/GB04/002450	9. Jun. 2004		

(Case Ref. P0223)

<b>Territory</b>	<b>Application No.</b>	<b>Application date</b>	<b>Patent No.</b>	<b>Date of grant</b>
PCT	PCT/GB05/000071	11. Jan. 2005		